
Sinopharm Group Co. Ltd.
1099.HKHKSEHealthcareMedical - Distribution
最新資料
HK$16.22
−HK$0.43 · -2.58%
1099.HK公司概覽
盤中時間採用HKT。市場資料可能有所延遲。
公司概況
公司網站Sinopharm Group Co. Ltd. is a prominent player in the People's Republic of China's healthcare market, specializing in the wholesale and retail of pharmaceuticals, medical devices, and related health products. The company's business activities are organized across four main divisions. Its Pharmaceutical Distribution segment supplies pharmaceutical goods to a wide range of clients, including hospitals, fellow distributors, retail pharmacies, and clinics. This division additionally offers extensive distribution, logistics, and value-added support to both domestic and international manufacturers and suppliers in the pharmaceutical and healthcare sectors. The Medical Devices segment is solely focused on the distribution of various medical equipment. Through its Retail Pharmacy division, Sinopharm manages and franchises a vast chain of drug stores, with an impressive 10,259 locations as of December 31, 2021. The "Other Business" segment is involved in the manufacturing and sale of pharmaceutical products, chemical reagents, and laboratory supplies. Beyond these core areas, the company also engages in property rental and management. It further distributes specialized items such as medical instruments, traditional Chinese herbal medicines, antibiotics, and biological products. Sinopharm provides a comprehensive array of services, including IT development, medicine and health consultations, investment services, import/export facilitation for goods and technology, various business and market information consulting, and the organization of conventions and exhibitions. Moreover, it oversees medical project investments, offers related consulting, and provides technological training. Notably, Sinopharm Group has established a strategic alliance with I-Mab to enhance its commercial capabilities and accelerate its market entry strategies. Founded in Shanghai, China, in 2003, Sinopharm Group Co. Ltd. operates as a subsidiary of Sinopharm Industrial Investment Co., Ltd.
- 產業
- Medical - Distribution
- 部門
- Healthcare
- 總部
- CN
- 執行長
- Wanyong Lian
- 上市以來
- 2009年9月23日
- 僱員
- 94,910
市場位置
日內區間
目前HK$16.22,
52週區間
目前HK$16.22,
- 開盤價
- HK$16.65
- 前收盤價
- HK$16.65
- 成交量
- 271.21萬
- 0.47× 平均值
- 平均成交量
- 576.45萬
- 日均成交量
- 市值
- 506.17億 HKD
- 貝塔
- 0.45
- 市場參考 1
- 50天平均值
- HK$16.877
- 低於平均水平-3.89%
- 200天平均值
- HK$19.2303
- 低於平均水平-15.65%
財務數據
財務快照
最近十二個月估值與收益率
- 本益比(TTM)
- 6.08×
- 股價淨值比(TTM)
- 0.52×
- 股價營收比(TTM)
- 0.08×
- 股息率
- 4.87%
獲利能力和效率
- 毛利率
- 7.32%
- 營業利益率
- 2.74%
- 淨利潤率
- 1.24%
財務健康
- 負債權益比
- 1.29×
- 奧特曼 Z 分數
- 3.89
- 皮奧特羅斯基 F 分數
- 7 共 9 個
財務報表
利潤率趨勢
獲利能力占已公布營收的百分比。
損益趨勢
營收
營業利益
淨利
| 項目(CNY) | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 5751.68億 CNY | 5845.08億 CNY | 5965.7億 CNY | 5521.48億 CNY | 5210.51億 CNY |
| 銷貨成本 | 5334.96億 CNY | 5402.53億 CNY | 5480.58億 CNY | 5047.13億 CNY | 4770.01億 CNY |
| 毛利 | 416.72億 CNY | 442.55億 CNY | 485.12億 CNY | 474.34億 CNY | 440.51億 CNY |
| 銷售、一般及管理費用 | 240.19億 CNY | 255.72億 CNY | 261.5億 CNY | 249.03億 CNY | 231.99億 CNY |
| 營業費用 | 256.34億 CNY | 280.67億 CNY | 283.02億 CNY | 268.3億 CNY | 243.39億 CNY |
| 利息收入 | 5億 CNY | 6.17億 CNY | 5.26億 CNY | 5.43億 CNY | 5.59億 CNY |
| 利息支出 | 23億 CNY | 27.34億 CNY | 29.57億 CNY | 35.2億 CNY | 37.57億 CNY |
| 折舊和攤銷 | 20.34億 CNY | 23.56億 CNY | 44.3億 CNY | 41.65億 CNY | 39.22億 CNY |
| 營業利益 | 160.38億 CNY | 161.88億 CNY | 202.09億 CNY | 206.04億 CNY | 197.12億 CNY |
| 淨利 | 71.55億 CNY | 70.5億 CNY | 90.54億 CNY | 85.26億 CNY | 77.59億 CNY |
公司資料更新於 2026年8月24日。
財報歷史與展望
- EPS優於預期率
- 50%
- 優於預期5次、低於預期5次、符合預期0次
- 平均EPS意外幅度
- -1.83%
- 10 類似報告
- 最新每股收益結果
- 1.31
- 預估1.27 · 優於預期3.15%
EPS:實際值與預估值
近期已公布業績
營收:實際值與預估值
近期已公布業績
1099.HK同業公司
持有1099.HK的ETF
報告持有此股票曝險的交易所交易基金。
Vanguard Total International Stock ETFVXUS4526.23萬0.01%6462億 USD0.05%US$87.71+0.78%
Vanguard FTSE Emerging Markets ETFVWO4197.16萬0.02%1623億 USD0.06%US$60.45+0.72%
iShares Core MSCI Emerging Markets ETFIEMG2920.48萬0.02%1600.01億 USD0.09%US$81.57+0.64%
Avantis Emerging Markets Equity ETFAVEM1844.16萬0.07%278.86億 USD0.33%US$94.24+0.75%
Schwab Fundamental Emerging Markets Large Company Index ETFFNDE1701.97萬0.17%101.99億 USD0.39%US$41.87+0.92%
Vanguard FTSE All-World ex-US ETFVEU766.78萬0.01%959億 USD0.04%US$85.69+0.82%
iShares MSCI Emerging Markets ETFEEM700.31萬0.02%312.24億 USD0.72%US$67.12+0.75%
iShares MSCI China ETFMCHI694.48萬0.11%62.89億 USD0.59%US$55.66+0.27%
Vanguard Total International Stock ETFVXUS- 市場價值
- 4526.23萬
- 重量
- 0.01%
- AUM
- 6462億 USD
- 費用率
- 0.05%
- 價格 / 1日
- US$87.71+0.78%
Vanguard FTSE Emerging Markets ETFVWO- 市場價值
- 4197.16萬
- 重量
- 0.02%
- AUM
- 1623億 USD
- 費用率
- 0.06%
- 價格 / 1日
- US$60.45+0.72%
iShares Core MSCI Emerging Markets ETFIEMG- 市場價值
- 2920.48萬
- 重量
- 0.02%
- AUM
- 1600.01億 USD
- 費用率
- 0.09%
- 價格 / 1日
- US$81.57+0.64%
Avantis Emerging Markets Equity ETFAVEM- 市場價值
- 1844.16萬
- 重量
- 0.07%
- AUM
- 278.86億 USD
- 費用率
- 0.33%
- 價格 / 1日
- US$94.24+0.75%
Schwab Fundamental Emerging Markets Large Company Index ETFFNDE- 市場價值
- 1701.97萬
- 重量
- 0.17%
- AUM
- 101.99億 USD
- 費用率
- 0.39%
- 價格 / 1日
- US$41.87+0.92%
Vanguard FTSE All-World ex-US ETFVEU- 市場價值
- 766.78萬
- 重量
- 0.01%
- AUM
- 959億 USD
- 費用率
- 0.04%
- 價格 / 1日
- US$85.69+0.82%
iShares MSCI Emerging Markets ETFEEM- 市場價值
- 700.31萬
- 重量
- 0.02%
- AUM
- 312.24億 USD
- 費用率
- 0.72%
- 價格 / 1日
- US$67.12+0.75%
iShares MSCI China ETFMCHI- 市場價值
- 694.48萬
- 重量
- 0.11%
- AUM
- 62.89億 USD
- 費用率
- 0.59%
- 價格 / 1日
- US$55.66+0.27%
繼續GoAI的研究
在 GoAI 中研究1099.HKresearch.disclaimer





